BAX - Baxter International Inc.

NYSE - Nasdaq Real-time price. Currency in USD
67.39
+0.34 (+0.51%)
As of 11:10AM EDT. Market open.
Stock chart is not supported by your current browser
Previous close67.05
Open67.31
Bid67.35 x 200
Ask67.36 x 200
Day's range66.96 - 67.41
52-week range53.04 - 72.58
Volume583,892
Avg. volume3,220,837
Market cap36.243B
Beta1.07
PE ratio (TTM)52.36
EPS (TTM)1.29
Earnings date26 Apr 2018
Forward dividend & yield0.64 (0.97%)
Ex-dividend date2018-03-01
1y target est75.71
Trade prices are not sourced from all markets
  • Financial Timesyesterday

    [$$] Allied Healthcare lines up rescue plan

    One of the biggest providers of home care visits for the elderly and unwell has warned that it could go bust unless creditors back a rescue plan. Allied Healthcare, which cares for about 13,500 people through contracts with 150 local authorities as well as out-of-hours GP services for the NHS, is filing for a company voluntary arrangement on Monday.

  • Can Hospital-Products Unit Aid Baxter (BAX) in Q1 Earnings?
    Zacks6 days ago

    Can Hospital-Products Unit Aid Baxter (BAX) in Q1 Earnings?

    Positive tidings on regulatory front, expanding Hospital-Products portfolio, strategic collaborations and strong presence in the international markets are key positives for Baxter's (BAX) Q1 results.

  • Zacks.com highlights: Baxter International, Copart, Applied Materials and Steel Dynamics
    Zacks7 days ago

    Zacks.com highlights: Baxter International, Copart, Applied Materials and Steel Dynamics

    Zacks.com highlights: Baxter International, Copart, Applied Materials and Steel Dynamics

  • 4 Top Stocks to Buy With Superb Efficiency Level
    Zacks10 days ago

    4 Top Stocks to Buy With Superb Efficiency Level

    Favorable efficiency level is expected to provide impressive returns as it is believed to be positively correlated with its price performance

  • Abbott Laboratories Goes Ex-Dividend on April 12, 2018
    Market Realist13 days ago

    Abbott Laboratories Goes Ex-Dividend on April 12, 2018

    The dividend will be payable on May 15, 2018, to shareholders of record on April 13, 2018. Abbott Laboratories is part of the S&P 500 Dividend Aristocrats, which are the companies that have paid out consistently increasing dividends to shareholders for at least 25 consecutive years. As of April 6, 2018, ABT stock has a dividend yield of 1.9%.

  • Varian Medical Systems: Expanding in Proton Therapy
    Market Realist17 days ago

    Varian Medical Systems: Expanding in Proton Therapy

    Should Investors Be Interested in Varian Medical Systems?

  • Discussing BDX’s Recent Stock Price Performance
    Market Realist24 days ago

    Discussing BDX’s Recent Stock Price Performance

    BDX's March 2018 Performance, Recommendations, and Updates

  • Top Analyst Reports for Netflix, PNC Financial & Mondelez
    Zacks25 days ago

    Top Analyst Reports for Netflix, PNC Financial & Mondelez

    Top Analyst Reports for Netflix, PNC Financial & Mondelez

  • Baxter International Created a New Reporting Structure for 2018
    Market Realist26 days ago

    Baxter International Created a New Reporting Structure for 2018

    Who Is Watching Baxter International in March 2018? For fiscal 2018, Baxter International (BAX) changed its reporting structure from the previous year. The company has two segments—Hospital Products and Renal—with a range of one to six global businesses.

  • Baxter International’s 2018 Revenues Expected to See Modest Rise
    Market Realist26 days ago

    Baxter International’s 2018 Revenues Expected to See Modest Rise

    Who Is Watching Baxter International in March 2018? For fiscal 2017, Baxter International (BAX) reported revenues of ~$10.6 billion, which represents 4.0% YoY growth on a reported basis and a 5.0% rise on an operational basis. The company has projected its annual revenues for 2018 to be 6.0%–7.0% higher year-over-year (or YoY) on a reported basis.

  • Analysts’ March 2018 Ratings for Baxter International and Peers
    Market Realist27 days ago

    Analysts’ March 2018 Ratings for Baxter International and Peers

    Who Is Watching Baxter International in March 2018? Baxter International’s (BAX) top-line performance in 4Q17 was mainly driven by increased demand for the company’s Fluid Systems’ products. Baxter International also witnessed rising demand for its cytotoxic contract manufacturing services.

  • Baxter (BAX) Banks on Portfolio Strength, Strategic Buyouts
    Zacks27 days ago

    Baxter (BAX) Banks on Portfolio Strength, Strategic Buyouts

    Baxter (BAX) gains on a slew of regulatory approvals and strategic collaborations.

  • Top Analyst Reports for Nike, Eli Lilly & NVIDIA
    Zacks28 days ago

    Top Analyst Reports for Nike, Eli Lilly & NVIDIA

    Top Analyst Reports for Nike, Eli Lilly & NVIDIA

  • Baxter International Completes Its Mallinckrodt Assets Buy
    Market Realistlast month

    Baxter International Completes Its Mallinckrodt Assets Buy

    Baxter International (BAX) announced the completion of its acquisition of Recothrom and Preveleak assets from Mallinckrodt Pharmaceuticals (MNK) for a total consideration of $185.0 million. This transaction includes $153.0 million in upfront payments and the rest in future milestone-based payments. Additionally, Baxter International has assumed Preveleak’s associated expenses and the contingent liabilities. Preveleak’s manufacturing operations are also included in the deal.

  • Baxter (BAX) Closes Acquisition of RECOTHROM & PREVELEAK
    Zackslast month

    Baxter (BAX) Closes Acquisition of RECOTHROM & PREVELEAK

    Baxter (BAX) steadily focuses on improving its Advanced Surgery business.

  • Here's Why You Should Invest in Baxter International Now
    Zackslast month

    Here's Why You Should Invest in Baxter International Now

    Recent buyouts and positive regulatory tidings boost investors' confidence on Baxter International (BAX).

  • What Investors Should Know about TMO’s Dividends
    Market Realistlast month

    What Investors Should Know about TMO’s Dividends

    What Analysts Recommend for Thermo Fisher Scientific

  • Behind Dentsply Sirona’s Total Impairment Charges in 2017
    Market Realistlast month

    Behind Dentsply Sirona’s Total Impairment Charges in 2017

    Dentsply Sirona (XRAY) updated its estimates and assumptions during fiscal 2Q17 and underwent an annual impairment test of goodwill. According to company estimates, the goodwill charges associated with some of its technologies segment businesses, including CAD-CAM imaging and its treatment center, came from impairment. The company recorded nearly $1.1 billion in goodwill impairment charges in 2Q17 and $581 million in 4Q17, for a total of ~$1.67 billion in fiscal 2017. Meanwhile, the company undertook an annual impairment assessment of indefinite-lived intangible assets.

  • What’s Stryker’s Guidance for 2018 and Beyond?
    Market Realist2 months ago

    What’s Stryker’s Guidance for 2018 and Beyond?

    The Latest on Stryker's Recent Developments and 2018 Expectations

  • Mallinckrodt (MNK) Up on Earnings and Revenues Beat in Q4
    Zacks2 months ago

    Mallinckrodt (MNK) Up on Earnings and Revenues Beat in Q4

    Mallinckrodt (MNK) shares gained as the company beat both earnings and revenue estimates in the fourth quarter as Inomax sales revived somewhat.

  • Why Abiomed’s Product Pipeline Looks Promising
    Market Realist2 months ago

    Why Abiomed’s Product Pipeline Looks Promising

    Abiomed (ABMD) is strategically focused on the market penetration of the company’s family of Impella heart pumps. The Impella device portfolio consists of Impella 2.5, Impella CP, Impella RP, Impella LD, and Impella 5.0 devices. To this end, Abiomed discontinued the sale of its AB5000 device used for heart surgery.

  • What Analysts Recommend for Abiomed and Peers in February 2018
    Market Realist2 months ago

    What Analysts Recommend for Abiomed and Peers in February 2018

    Abiomed (ABMD) is a supplier of mechanical circulatory support devices and offers a continuum of care to heart failure patients. Abiomed develops, manufactures, and commercializes products designed to improve the blood flow and perform the pumping function of the heart. Of the ten analysts covering Abiomed (ABMD) in February 2018, five analysts have given the stock a “strong buy” rating, three analysts have given it a “buy” rating, while two analysts have given it a “hold” rating.

  • Abbott Laboratories’ Stock Performance after a Recent Bull Run
    Market Realist2 months ago

    Abbott Laboratories’ Stock Performance after a Recent Bull Run

    Abbott Laboratories Updates: Dividend, Ratings, and More

  • Analysts’ Ratings for NxStage Medical and Peers in February 2018
    Market Realist2 months ago

    Analysts’ Ratings for NxStage Medical and Peers in February 2018

    Headquartered in Lawrence, Massachusetts, NxStage Medical (NXTM) is a medical technology company with a focus on developing, manufacturing, and marketing innovative products targeted at patients suffering from chronic or acute kidney failure. The company also operates NxStage kidney care dialysis centers, which treat end-stage renal disease (or ESRD) patients. NxStage Medical’s primary product is System One, which is capable of delivering the therapeutic flexibility and clinical benefits of traditional dialysis machines in a smaller, portable, and easy-to-use format.